CN109415733A - 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用 - Google Patents

用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用 Download PDF

Info

Publication number
CN109415733A
CN109415733A CN201780040430.8A CN201780040430A CN109415733A CN 109415733 A CN109415733 A CN 109415733A CN 201780040430 A CN201780040430 A CN 201780040430A CN 109415733 A CN109415733 A CN 109415733A
Authority
CN
China
Prior art keywords
seq
sequence
shmir
nucleic acid
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780040430.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·马奥
D·苏伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Benitec Biopharma Ltd
Original Assignee
Benitec Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benitec Biopharma Ltd filed Critical Benitec Biopharma Ltd
Publication of CN109415733A publication Critical patent/CN109415733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780040430.8A 2016-05-05 2017-05-05 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用 Pending CN109415733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332245P 2016-05-05 2016-05-05
US62/332,245 2016-05-05
PCT/AU2017/050413 WO2017190197A1 (en) 2016-05-05 2017-05-05 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Publications (1)

Publication Number Publication Date
CN109415733A true CN109415733A (zh) 2019-03-01

Family

ID=60202535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780040430.8A Pending CN109415733A (zh) 2016-05-05 2017-05-05 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用

Country Status (11)

Country Link
US (2) US11535851B2 (enExample)
EP (1) EP3452595A4 (enExample)
JP (1) JP2019514401A (enExample)
KR (1) KR102358280B1 (enExample)
CN (1) CN109415733A (enExample)
AU (2) AU2017260580B2 (enExample)
CA (1) CA3023185A1 (enExample)
PH (1) PH12018502320A1 (enExample)
RU (2) RU2748806C2 (enExample)
SG (1) SG11201809753YA (enExample)
WO (1) WO2017190197A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452595A4 (en) * 2016-05-05 2020-02-19 Benitec Biopharma Limited REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
JP7441174B2 (ja) * 2018-11-16 2024-02-29 公益財団法人東京都医学総合研究所 Ｂ型肝炎ウイルスの複製阻害組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
CN101603042A (zh) * 2008-06-13 2009-12-16 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
US20120035240A1 (en) * 2003-06-12 2012-02-09 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
CN102575248A (zh) * 2009-06-05 2012-07-11 薛大寓 用于抑制单或多靶基因的多顺反子shRNA表达盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
RU2217161C2 (ru) * 1997-08-26 2003-11-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) Способ лечения вирусного гепатита
JP4210737B2 (ja) * 2001-07-12 2009-01-21 ユニバーシティー オブ マサチューセッツ 遺伝子サイレンシングを仲介する低分子干渉リボ核酸のインビボにおける製造方法
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
AU2005319306B9 (en) 2004-12-22 2012-04-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
US20130267429A1 (en) * 2009-12-21 2013-10-10 Lawrence Livermore National Security, Llc Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes
KR20180110186A (ko) 2010-10-28 2018-10-08 베니텍 바이오파마 리미티드 Hbv 치료
KR102434346B1 (ko) * 2011-06-30 2022-08-18 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
HRP20220607T1 (hr) * 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
WO2014117050A2 (en) * 2013-01-26 2014-07-31 Mirimus, Inc. Modified mirna as a scaffold for shrna
CN103088026A (zh) 2013-02-01 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 抗乙型肝炎病毒人工miRNA及其组合
PL243776B1 (pl) * 2013-09-02 2023-10-09 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG
SG11201708679YA (en) * 2015-05-06 2017-11-29 Benitec Biopharma Ltd Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EP3452595A4 (en) * 2016-05-05 2020-02-19 Benitec Biopharma Limited REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035240A1 (en) * 2003-06-12 2012-02-09 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
CN101603042A (zh) * 2008-06-13 2009-12-16 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
CN102575248A (zh) * 2009-06-05 2012-07-11 薛大寓 用于抑制单或多靶基因的多顺反子shRNA表达盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONG CHEN等: "siRNA Pool Targeting Different Sites of Human Hepatitis B Surface Antigen Efficiently Inhibits HBV Infection", 《J DRUG TARGET》 *

Also Published As

Publication number Publication date
AU2017260580A1 (en) 2018-11-22
US20190338285A1 (en) 2019-11-07
RU2018142797A (ru) 2020-06-05
US11535851B2 (en) 2022-12-27
KR102358280B1 (ko) 2022-02-07
AU2022241489A1 (en) 2022-10-20
CA3023185A1 (en) 2017-11-09
RU2021113126A (ru) 2021-08-20
RU2748806C2 (ru) 2021-05-31
US20230093951A1 (en) 2023-03-30
PH12018502320A1 (en) 2022-01-24
EP3452595A1 (en) 2019-03-13
SG11201809753YA (en) 2018-12-28
KR20190003756A (ko) 2019-01-09
WO2017190197A1 (en) 2017-11-09
EP3452595A4 (en) 2020-02-19
AU2017260580B2 (en) 2022-07-28
RU2018142797A3 (enExample) 2020-09-10
JP2019514401A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
JP5593279B2 (ja) 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列
JP5934310B2 (ja) 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
JP7191690B2 (ja) Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬及びその使用
JP2011507554A (ja) 遺伝子発現を増加させるための方法および組成物
JP2023062092A (ja) 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用
US20230093951A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
US9771589B2 (en) Treating hepatitis virus infection by modulating microRNAs miR-130a, miR-130b, miR-204, or miR-1236
WO2024131946A1 (zh) 核酸分子及其应用
Betty Mowa et al. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs
JP2024515654A (ja) Ｈ－１ ＰＶ発現ＲＮＡｉエフェクター
JP2022508835A (ja) 眼咽頭筋ジストロフィー（ｏｐｍｄ）を治療するための方法
JP7441174B2 (ja) Ｂ型肝炎ウイルスの複製阻害組成物
JP4536112B2 (ja) ＲＮＡｉ耐性ウイルス株を克服する新手法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20231017

AD01 Patent right deemed abandoned